How did BMRA's Q3 earnings surprise investors?

Biomerica's Q3 earnings did not surprise investors, as the company's full-year 2024 earnings report revealed a 1.4% increase in total revenue and a significant reduction in net loss compared to the previous year. However, the stock's performance has been under pressure, with a recent plunge to a 52-week low of $0.28 and a trading low of $0.44, below its 200-day moving average of $0.83. Despite these challenges, analysts anticipate sales growth for the current year, and there's an expectation for net income to improve. |code|Ticker|Name|Date|Closing Price|market_code| |---|---|---|---|---|---| |BMRA|BMRA.O|Biomerica|20250404|0.5002|186| |code|Ticker|Name|Date|Net Income YoY|Net Income|market_code| |---|---|---|---|---|---|---| |BMRA|BMRA.O|Biomerica|2024 Q1|45.366795366795365|-1132000|186| |BMRA|BMRA.O|Biomerica|2024 Q2|7.318573185731856|-1507000|186| |BMRA|BMRA.O|Biomerica|2024 Q3|-16.242424242424242|-1918000|186| |BMRA|BMRA.O|Biomerica|2024 Q4|20.703125|-1421000|186|